No headlines found.
Globe Newswire (Fri, 6-Dec 5:30 PM ET)
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
Globe Newswire (Thu, 7-Nov 4:05 PM ET)
Globe Newswire (Tue, 22-Oct 7:00 AM ET)
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
Athira Pharma trades on the NASDAQ stock market under the symbol ATHA.
As of January 14, 2025, ATHA stock price was flat at $0.53 with 99,677 million shares trading.
ATHA has a beta of 6.00, meaning it tends to be more sensitive to market movements. ATHA has a correlation of 0.16 to the broad based SPY ETF.
ATHA has a market cap of $20.57 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ATHA traded as high as $14.22 and as low as $.41.
The top ETF exchange traded funds that ATHA belongs to (by Net Assets): VTI, VXF, IWC.
ATHA has underperformed the market in the last year with a price return of -82.3% while the SPY ETF gained +23.6%. However, in the short term, ATHA had mixed performance relative to the market. It has outperformed in the last 3 months, returning +27.9% vs +0.8% return in SPY. But in the last 2 weeks, ATHA shares have been beat by the market, returning -2.9% compared to an SPY return of -1.0%.
ATHA support price is $.50 and resistance is $.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATHA shares will trade within this expected range on the day.